This study suggested that though arsenic methylated metabolites could not induce cellular differentiation or PML-RARα fusion protein degradation in APL cells, but still are potent inducer of cellular apoptosis as compared to their precursor iAsIII and therefore, the arsenic metabolites might be used in leukemia and lymphoma treatments [193]. This evidence concerns the gene PML and acute promyelocytic leukemia.